In 2013, after learning that the lack of an animal model was hindering research for a cure for Usher 1F, Usher 1F Collaborative was founded. Fast forward six years. We now have our two animal models, a zebrafish and a mouse. We just held our second Usher 1F researchers meeting in Vancouver, Canada. The room was an exciting sight, filled with nine researchers, two pharmaceutical company representatives, and seven parents. Eight researchers updated us on their work toward multiple paths to an effective treatment. Now that we have our animal models, the presentations focused on treatments in development and on collaborations to test these treatments in our animal models. We have done the background work, and now we are ready for the exciting part.

Because of our foundation's work, awareness of and interest in Usher 1F research has grown in the scientific research community, and, consequently, so have our opportunities to develop more paths to a cure. At present, we have seven labs working to develop a cure for the vision loss of Usher 1F, with collaboration among many of them, in particular with the researchers working on gene and drug therapies using our animal models to test these treatments. While this is all incredibly exciting and encouraging, it is also expensive. We have been fortunate to have a couple of our researchers obtain outside support, but without funding from Usher 1F Collaborative, most of this promising research would come to a halt.

Please consider making a gift today to Usher 1F Collaborative to help us ensure that our momentum continues. We are in a race against time to save the vision of those with this devastating disease, and we need your help to ensure that we win this race.
Our second Usher 1F researchers meeting was an exciting event. On May 2, 2019, nine researchers, two pharmaceutical company representatives, and seven parents gathered to hear updates on research for a cure for the vision loss of Usher 1F. Highlights of the research presentations include:

• Our zebrafish Usher 1F model from Dr. Monte Westerfield's lab at the University of Oregon is complete, and collaboration is beginning to test drugs and gene therapies for efficacy. In particular, Dr. David Corey of Harvard Medical School has developed mini genes to be tested in our zebrafish.

• Our mouse model is complete, and Dr. Zubair Ahmed at the University of Maryland will soon begin testing for efficacy split genes that Dr. Livia Carvalho developed in her lab at the University of Western Australia.

• Dr. Leah Byrne at the University of Pittsburgh came on board at the beginning of 2019, and she has begun developing a split gene as well using a unique approach she has developed. Dr. Byrne's split gene constructs will also be tested in our mouse model at the University of Maryland. Drs. Byrne and Carvalho met at our meeting and are now excited to collaborate, which will speed the pace of work.

• Dr. Budd Tucker of the University of Iowa presented his work on using Dr. David Liu’s pioneering base editing approach for Usher 1F. His work has been funded by a very generous grant from the Australian government.

• Dr. Alex Hewitt of the Centre for Eye Research Australia presented his work on using Dr. David Liu’s pioneering base editing approach for Usher 1F. His work has been funded by a very generous grant from the Australian government.

• Eloxx Pharmaceuticals has drug compounds that are applicable to Usher 1F. Their representative met with Drs. Westerfield and Ahmed and is working to obtain these compounds for them to test on our animal models.

• A representative from Oxford Biomedica also attended the meeting. This is the company that developed the gene replacement for Usher 1B. While they are interested in Usher 1F, we will first need a natural history study, that is documentation from testing on patients with Usher 1F of the natural progression of vision loss over time to be used as a basis of comparison. We are working to obtain this data.

All the meeting attendees came away feeling excited and hopeful, with the researchers asking us to convene another meeting again in conjunction with the international Association for Research in Vision and Ophthalmology (ARVO) conference in the spring of 2020.

SEND DONATIONS
Usher 1F Collaborative
#228
321 Walnut Street
Newtonville, MA 02460-1927
www.Usher1F.org